Accessibility StatementSkip Navigation Citius Oncology's LYMPHIRâ"¢ exhibit will be located at Booth #265 LYMPHIR launch on track for Q4 2025 CRANFORD, N.J., Nov. 25, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced it will exhibit at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place December 6–9, 2025, in Orlando, Florida. The ...

Biotech and healthcare stocks saw notable activity in Friday's after-hours trading session, with several names posting sharp moves on the back of corporate updates and investor anticipation. Here are the highlights from November 21, 2025.Butterfly Network, Inc. (BFLY) shares climbed in extended trading, rising 6.04% to $2.81 after adding $0.16. At the close, the stock had already surged 14.22% to $2.65. The digital company announced that CEO Joseph DeVivo and Interim CFO Megan Carlson will participate in a ...

Core Insights - Citius Oncology is enhancing its commercial strategy for the launch of LYMPHIR, a novel immunotherapy for cutaneous T-cell lymphoma, through a collaboration with Verix and its Tovana platform, which utilizes AI and machine learning for salesforce targeting and engagement [1][2][3] Company Overview - Citius Oncology, a subsidiary of Citius Pharmaceuticals, focuses on developing and commercializing innovative oncology therapies, with LYMPHIR being its primary asset approved by the FDA in August 2024 for treating relapsed or refractory Stage I-III cutaneous T-cell lymphoma [1][34][36] - The company aims to penetrate a market estimated to exceed $400 million, which is currently underserved by existing therapies [34] Product Details - LYMPHIR (denileukin diftitox-cxdl) is a targeted immune therapy indicated for adult patients with relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy [10][34] - The drug works by binding to IL-2 receptors on cancer cells, leading to cell death through inhibition of protein synthesis [6][7] Collaboration and Technology - The partnership with Verix aims to leverage the Tovana platform for real-time analytics and data-driven decision-making, enhancing the efficiency of Citius Oncology's commercial team [2][4][5] - The Tovana platform integrates advanced analytics and real-world claims data to refine targeting and support predictive intelligence in sales and marketing [2][4] Market Strategy - Citius Oncology is focused on capital efficiency and sustainable value creation for shareholders while facilitating access to care for patients with cutaneous T-cell lymphoma [5] - The company has established foundational launch activities, including distribution partnerships and reimbursement codes, to support the commercialization of LYMPHIR [4][5]

Core Insights - U.S. stock futures showed slight gains, with Dow futures up approximately 0.1% [1] Company Performance - PACCAR Inc reported a significant decline in shares, falling 18.3% to $7.64 in pre-market trading after disappointing third-quarter results [1] - The company's quarterly earnings were $1.12 per share, missing the analyst consensus estimate of $1.17 per share [1] - PACCAR's quarterly sales were reported at $6.107 billion, also below the analyst consensus estimate of $6.371 billion [1] Other Stocks Movement - Neuphoria Therapeutics Inc shares plummeted 65.3% to $5.35 after its AFFIRM-1 trial for social anxiety failed to meet endpoints [4] - Citius Pharmaceuticals Inc shares fell 18.2% to $1.48 following a $6 million registered direct offering announcement [4] - Galapagos NV shares declined 15.4% to $28.99 as the company plans to wind down its Cell Therapy Business [4] - Silvercorp Metals Inc shares decreased by 9.9% to $6.35 in pre-market trading [4] - Other notable declines included Theravance Biopharma Inc down 8.6% to $13.07 and Pacira Biosciences Inc down 8.3% to $21.10 [4]

Summary of Key Points Core Viewpoint - U.S. stock futures showed slight gains, with the Dow futures increasing by approximately 0.1% on Tuesday, while several companies experienced significant declines in pre-market trading due to disappointing earnings or other negative news [1]. Company-Specific Summaries - **PACCAR Inc (NASDAQ:PCAR)**: - Shares fell 18.3% to $7.64 after reporting third-quarter earnings of $1.12 per share, missing the analyst consensus estimate of $1.17 per share. - Quarterly sales were reported at $6.107 billion, also below the consensus estimate of $6.371 billion [1]. - **Neuphoria Therapeutics Inc (NASDAQ:NEUP)**: - Shares dropped 65.3% to $5.35 following the failure of its AFFIRM-1 trial for social anxiety to meet endpoints [4]. - **Citius Pharmaceuticals Inc (NASDAQ:CTXR)**: - Shares decreased by 18.2% to $1.48 after announcing a $6 million registered direct offering [4]. - **Galapagos NV – ADR (NASDAQ:GLPG)**: - Shares declined 15.4% to $28.99 as the company announced plans to wind down its Cell Therapy Business as part of a transformation strategy [4]. - **Silvercorp Metals Inc (NYSE:SVM)**: - Shares fell 9.9% to $6.35 in pre-market trading [4]. - **Theravance Biopharma Inc (NASDAQ:TBPH)**: - Shares decreased by 8.6% to $13.07 [4]. - **Pacira Biosciences Inc (NASDAQ:PCRX)**: - Shares dipped 8.3% to $21.10; the company is set to present new data from a Phase 1 clinical trial for a gene therapy candidate at an upcoming meeting [4]. - **Coeur Mining Inc (NYSE:CDE)**: - Shares fell 8.2% to $20.22 after a previous gain of 5% on Monday [4]. - **Endeavour Silver Corp (NYSE:EXK)**: - Shares declined 8.2% to $8.57 [4]. - **Sibanye Stillwater Ltd (NYSE:SBSW)**: - Shares fell 8.1% to $10.67 [4]. - **First Majestic Silver Corp (NYSE:AG)**: - Shares declined 7.9% to $13.22 [4]. - **Hycroft Mining Holding Corporation (NYSE:HYMC)**: - Shares dipped 7.7% to $8.03 [4]. - **Harmony Gold Mining Company Ltd (NYSE:HMY)**: - Shares declined 6.8% to $18.85 [4]. - **Pan American Silver Corp (NYSE:PAAS)**: - Shares fell 6.6% to $36.80 [4].

Core Insights - Citius Pharmaceuticals and Citius Oncology will participate in three investor conferences in October 2025, providing opportunities for one-on-one meetings with management [1][2][3]. Company Overview - Citius Pharmaceuticals, Inc. is focused on developing first-in-class critical care products, with FDA approval for LYMPHIR, a targeted immunotherapy for cutaneous T-cell lymphoma, received in August 2024 [4]. - Citius Pharmaceuticals' late-stage pipeline includes Mino-Lok, an antibiotic lock solution, and CITI-002 (Halo-Lido), a topical formulation for hemorrhoid relief, with successful trial completions in 2023 [4]. - Citius Pharmaceuticals owns 79% of Citius Oncology, which specializes in novel targeted oncology therapies [4][5]. Market Potential - The initial market for LYMPHIR is estimated to exceed $400 million and is considered underserved by existing therapies, indicating significant growth potential [5]. - Citius Oncology has robust intellectual property protections, including orphan drug designation and pending patents, which enhance its competitive positioning in the oncology market [5][6].

Core Insights - Citius Oncology has finalized an exclusive agreement with EVERSANA to support the commercialization of LYMPHIR, an FDA-approved therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL), expected to launch in Q4 2025 [1][4][27] Company Overview - Citius Oncology is a subsidiary of Citius Pharmaceuticals, focused on developing and commercializing targeted oncology therapies. The company’s primary asset, LYMPHIR, received FDA approval in August 2024 for treating adults with relapsed or refractory CTCL after at least one prior systemic therapy [27][28] - Citius Oncology estimates the initial market for LYMPHIR exceeds $400 million and is growing, indicating a significant opportunity in an underserved market [27] Product Details - LYMPHIR (denileukin diftitox-cxdl) is a targeted immune therapy indicated for adult patients with relapsed or refractory Stage I-III CTCL after at least one prior systemic therapy. It works by binding to IL-2 receptors on malignant T-cells, leading to cell death [6][8][27] - The therapy has demonstrated the ability to deplete immunosuppressive regulatory T lymphocytes and exhibit antitumor activity [7] Commercialization Strategy - Under the Master Service Agreement, EVERSANA will provide an integrated suite of pre- and post-launch operations services, including medical information, pharmacovigilance, revenue cycle management, and data analytics [2][3] - This partnership is expected to enhance Citius Oncology's operational readiness and market access for LYMPHIR, aligning with investor expectations [4][29] Market Context - Cutaneous T-cell lymphoma is the most common type of cutaneous lymphoma, with a significant impact on patients' quality of life due to severe symptoms. The disease primarily affects men aged 50 to 60 [5][27] - Current treatment options for advanced CTCL are limited, with no curative therapies available other than allogeneic stem cell transplantation for a small fraction of patients [5]

Core Viewpoint - Citius Oncology, Inc. has successfully closed a registered direct offering and concurrent private placement, raising approximately $9.0 million through the sale of 5,142,858 shares of common stock and warrants [1][2]. Group 1: Offering Details - The effective offering price for each share of common stock and accompanying warrant was $1.75, with warrants having an exercise price of $1.84 per share [1]. - The warrants will be exercisable six months from the date of issuance and will expire on the five and one-half year anniversary from the date of issuance [1]. - Maxim Group LLC acted as the sole placement agent for the offering, which was conducted under a registration statement filed with the SEC [3]. Group 2: Company Overview - Citius Oncology is focused on developing and commercializing novel targeted oncology therapies, with its primary asset, LYMPHIR, approved by the FDA for treating relapsed or refractory CTCL [5]. - The initial market for LYMPHIR is estimated to exceed $400 million and is considered underserved by existing therapies [5]. - Citius Pharmaceuticals, the parent company, also has a late-stage pipeline including Mino-Lok® and CITI-002 (Halo-Lido) [6].

Core Viewpoint - Citius Oncology, Inc. has entered into a securities purchase agreement to raise approximately $9.0 million through a registered direct offering and a concurrent private placement, involving the sale of 5,142,858 shares of common stock and unregistered warrants [1][2]. Group 1: Offering Details - The effective offering price for each share of common stock and accompanying warrant is set at $1.75, with warrants having an exercise price of $1.84 per share, exercisable six months from issuance and expiring five and a half years later [1][2]. - The offering is expected to close around September 10, 2025, pending customary closing conditions [2]. Group 2: Company Background - Citius Oncology focuses on developing and commercializing novel targeted oncology therapies, with its primary asset, LYMPHIR, approved by the FDA for treating adults with relapsed or refractory CTCL [5]. - The initial market for LYMPHIR is estimated to exceed $400 million and is considered underserved by existing therapies, supported by robust intellectual property protections [5]. - Citius Pharmaceuticals, the parent company, is dedicated to first-in-class critical care products, with a late-stage pipeline that includes Mino-Lok® and CITI-002 (Halo-Lido) [6].

Core Insights - Citius Oncology has launched an innovative AI platform to enhance its commercial strategies and support the upcoming launch of LYMPHIR™, a novel therapy for cutaneous T-cell lymphoma (CTCL) [1][2][5] - The AI platform utilizes machine learning to identify treatment patterns and target prescribers effectively, thereby improving patient care and clinical decision-making [2][4][5] - LYMPHIR is a targeted immune therapy approved by the FDA in August 2024 for relapsed or refractory CTCL, with a market potential exceeding $400 million [6][7][32] Group 1: AI Platform and Commercial Strategy - The proprietary AI platform is designed to refine targeting and enhance the efficiency of the salesforce by providing data-informed engagement with healthcare providers [1][3] - It continuously learns from real-world data and marketing performance analytics, delivering predictive insights for tailored customer journeys [4] - The platform aims to optimize the commercial infrastructure and accelerate healthcare provider education [5] Group 2: Product Overview and Market Potential - LYMPHIR is indicated for adult patients with relapsed or refractory Stage I-III CTCL after at least one prior systemic therapy [10] - The therapy is a recombinant fusion protein that targets IL-2 receptors on tumor cells, leading to cell death and enhanced antitumor activity [6] - Citius Oncology estimates the initial market for LYMPHIR to exceed $400 million, indicating significant growth potential in an underserved market [32]